Health ministers want to provide better value for money, but that could mean restricting the availability of some drugs.
The idea that public health services should fund only the most effective drugs and procedures seems uncontroversial. Most people would agree that life-saving cancer drugs should be ‘in’ the public package, while tattooremoval and trivial cosmetic surgery should not.
But between those two extremes is a fuzzy grey area. Should a drug to treat Alzheimer's disease be prescribed only for people in advanced stages of the affliction? What about a drug that reduces the chance of cancerous tumours returning, but might increase the risk of heart disease?
These are the difficult choices that all healthcare providers have to grapple with. As a result, Europe is putting increasing emphasis on health technology assessment (HTA), the process of evaluating the medical, social, economic and ethical dimensions of new drugs, medical devices and surgical procedures.
Last December, European Union finance ministers pledged to use HTA more systematically as part of a wider effortto improve value for money of their health systems.
HTAs are not a new idea. The first HTA agency was set up in Sweden in the early 1990s, although some E U countries, especially in central and eastern Europe, have little tradition of using them.
Doc Link
- Persistem erros nos pagamentos aos Médicos pelo quarto mês consecutivo: Esgotou-se a paciência!19 abril 2024Esgotou-se a paciência! Pelo quarto mês consecutivo, há Unidades Locais de Saúde (ULS) que...
- CIT prévios a 2012: Remuneração na transição para a Dedicação Plena16 abril 2024Para os médicos com Contrato Individual de Trabalho prévios a 2012 e remuneração fora da tabela...
- Hospital das Forças Armadas: médicos civis podem aderir à Dedicação Plena09 abril 2024Os médicos civis do Hospital das Forças Armadas podem aderir ao regime de Dedicação...